Article Information
History
- September 29, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Dimitris Vavoulis1,2,*,
- Anthony Cutts1,
- Nishita Thota3,
- Jordan Brown3,
- Robert Sugar3,
- Antonio Rueda3,
- Arman Ardalan1,
- Flavia Matos Santo1,
- Thippesh Sannasiddappa3,
- Bronwen Miller3,
- Stephen Ash4,
- Yibin Liu5,6,
- Chun-Xiao Song4,7,
- Brian Nicholson8,
- Helene Dreau1,
- Carolyn Tregidgo3 and
- Anna Schuh1
- 1Oxford Molecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, UK
- 2Biomedical Research Centre, The Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
- 3Exact Sciences Innovation, The Sherard Bldg, Edmund Halley Rd, Littlemore, Oxford OX4 4DQ
- 4Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 5College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China
- 6Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430072, China
- 7Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 8Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
- ↵* Corresponding author; email: dimitris.vavoulis{at}gmail.com
Posted September 29, 2023.
Multimodal cell-free DNA whole-genome analysis combined with TET-Assisted Pyridine Borane Sequencing is sensitive and reveals specific cancer signals
